[ET Net News Agency, 26 May 2020] Sino Biopharmaceutical Limited (01177) said new drug
application of the anti PD-1 monoclonal antibody drug (generic name: Penpulimab; research
& development code: AK105) jointly developed and commercialized by the group and Akeso,
Inc. (09926) has been accepted by the National Medical Products Administration of the
People's Republic of China, for the treatment of patients with relapsed or refractory
Classical Hodgkin's Lymphoma.
Classical Hodgkin Lymphoma (cHL) is a B-cell lymphoma and is also one of the most common
malignancies among young people. (RC)